Form 4 Filing for Corcept Therapeutics Inc.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc., reported a sale of 5,000 shares of Common Stock on May 27, 2026, at a price of $65.00 per share. This transaction resulted in a post-transaction ownership of 6,230 shares. The filing also notes that 749 shares are subject to unvested restricted stock awards granted on June 2, 2025, 200 shares on September 2, 2025, 178 shares on December 1, 2025, and 398 shares on March 2, 2026. These awards vest fully on their one-year anniversary, contingent upon the reporting person meeting certain requirements.